140 related articles for article (PubMed ID: 1695522)
21. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
22. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
Bosl GJ; Head MD
Int J Biol Markers; 1994; 9(1):25-8. PubMed ID: 7519650
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
[TBL] [Abstract][Full Text] [Related]
24. The value of alpha-fetoprotein and beta-human chorionic gonadotrophin in the management of testicular tumours.
Narayana AS; Loening S; Culp DA
Br J Urol; 1978 Dec; 50(7):605-8. PubMed ID: 88986
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of pregnancy-specific beta 1-glycoprotein in patients with non-seminomatous testicular germ cell tumors.
de Bruijn HW; Suurmeijer AJ; Sleijfer DT; Koops HS; Ockhuizen T; Willemse PH; Marrink J
Eur J Cancer Clin Oncol; 1982 Oct; 18(10):911-6. PubMed ID: 6186495
[TBL] [Abstract][Full Text] [Related]
26. AFP and HCG in germ cell tumors.
Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
[TBL] [Abstract][Full Text] [Related]
27. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
[TBL] [Abstract][Full Text] [Related]
28. Testicular tumour markers in tissue correlated to serum levels and clinical stage.
Alm P; Hultberg B; Olsson AM
Scand J Urol Nephrol; 1984; 18(4):283-8. PubMed ID: 6209794
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis.
Droz JP; Kramar A; Ghosn M; Piot G; Rey A; Theodore C; Wibault P; Court BH; Perrin JL; Travagli JP
Cancer; 1988 Aug; 62(3):564-8. PubMed ID: 2455591
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin.
Fottner C; Sattarova S; Hoffmann K; Spöttl G; Weber MM
Eur J Endocrinol; 2008 Sep; 159(3):317-27. PubMed ID: 18524796
[TBL] [Abstract][Full Text] [Related]
32. Germ cell tumours of testis: prognostic factors and results.
Nikzas D; Champion AE; Fox M
Eur Urol; 1990; 18(4):242-7. PubMed ID: 1705226
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
35. Metastatic non-seminomatous germ cell tumour and dermatomyositis.
Barker RA; Currie DC; Horwich A; Spiro SG
Postgrad Med J; 1990 Jan; 66(771):59-60. PubMed ID: 1693426
[TBL] [Abstract][Full Text] [Related]
36. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
[TBL] [Abstract][Full Text] [Related]
37. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
38. [Tumor marker diagnosis in non-seminomatous testicular tumors using human chorionic gonadotropin (HCG) and alpha fetoprotein (AFP)].
Boewer C; Nawka S; Fleck H; Uibel M; Immer U; Schmidt HE; Herzmann H; Pilgrim G; Ziegenbein R
Z Urol Nephrol; 1985 Feb; 78(2):77-86. PubMed ID: 2581393
[TBL] [Abstract][Full Text] [Related]
39. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
von Eyben FE; Blaabjerg O; Madsen EL; Petersen PH; Smith-Sivertsen C; Gullberg B
Eur J Cancer; 1992; 28(2-3):410-5. PubMed ID: 1375486
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
